EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism

Jessica Kendrick iD, Markus Ketteler iD, Myles Wolf iD, Snezana Pesic iD, Biserka Tirmenstajn-Jankovic iD, Steven Zeig, Aaron Camp iD, Ellie Copeland, B T Slingsby, Bastian Dehmel, Geoffrey Block iD

Journal of the American Society of Nephrology · 23.10.2026

DOI: 10.1681/asn.0000001285 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 23.10.2026. Verfasst von Jessica Kendrick und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz, Aurora, Colorado. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pathalys Pharma Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points These 2 phase 3 trials assessed upacicalcet, an intravenous calcimimetic, in hemodialysis patients with secondary hyperparathyroidism. ≥30% reduction in intact parathyroid hormone levels occurred in 42% (Parathyroid Hormone [PTH] Attenuation Trial in Hemodialysis-1) and 44% (Parathyroid Hormone [PTH] Attenuation Trial in Hemodialysis-2) with upacicalcet versus 17% and 17%, respectively, with placebo (strata-adjusted; both P < 0.001). Asymptomatic hypocalcemia was more frequent with upacicalcet, and symptomatic hypocalcemia was infrequent; gastrointestinal events were similar to placebo.

Background

Secondary hyperparathyroidism is a common complication in patients with CKD undergoing hemodialysis. We examined the efficacy and safety of upacicalcet, an intravenous calcimimetic, versus placebo on serum intact parathyroid hormone (iPTH) levels in patients receiving hemodialysis.

Methods

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis (PATH)-1 and PATH-2 were identical, randomized, phase 3, double-blind, placebo-controlled trials conducted in parallel in 768 patients receiving hemodialysis with secondary hyperparathyroidism and serum iPTH levels ≥400 to ≤1500 pg/ml. Participants received intravenous upacicalcet ( n =510) or placebo ( n =258) after hemodialysis for 27 weeks; dosing was titrated using iPTH and corrected serum calcium. Calcium supplementation or changes in active vitamin D sterols for corrected serum calcium

Schlagwörter

Stichwörter der Autor:innen

CKDbones, stones, and mineral metabolismclinical trialmineral metabolism

Autor:innen und Institutionen

  • Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz, Aurora, Colorado.
  • Department of General Internal Medicine and Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany.
  • Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York-Presbyterian/Weill Cornell Medical Center, New York, New York.
  • Clinical Department of Nephrology and Metabolic Disorders With Dialysis "Prof. Dr. Vasilije Jovanovic" Zvezdara Clinical Hospital Center, Belgrade, Serbia.
  • Department of Nephrology and Hemodialysis, Health Center Zajecar, Zajecar, Serbia.
  • Memorial Healthcare System, Hollywood, Florida.

ORCID-Profile: Jessica Kendrick, Markus Ketteler, Myles Wolf, Snezana Pesic, Biserka Tirmenstajn-Jankovic, Aaron Camp, Geoffrey Block

Förderung

  • Pathalys Pharma Inc

Zitieren

APA

Kendrick, J., Ketteler, M., Wolf, M., Pesic, S., Tirmenstajn-Jankovic, B., Zeig, S., Camp, A., Copeland, E., Slingsby, B. T., Dehmel, B., & Block, G. (2026). Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000001285

Vancouver

Kendrick J, Ketteler M, Wolf M, Pesic S, Tirmenstajn-Jankovic B, Zeig S, et al. Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism. Journal of the American Society of Nephrology. 2026. doi:10.1681/asn.0000001285

BibTeX
@article{Kendrick2026,
  author = {Kendrick, Jessica and Ketteler, Markus and Wolf, Myles and Pesic, Snezana and Tirmenstajn-Jankovic, Biserka and Zeig, Steven and Camp, Aaron and Copeland, Ellie and Slingsby, B T and Dehmel, Bastian and Block, Geoffrey},
  title = {Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  doi = {10.1681/asn.0000001285}
}
Kostenlos starten →